Stock SNSE SENSEI BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.02 USD +1.99% Intraday chart for Sensei Biotherapeutics, Inc. +5.15% +47.40%
Apr. 24 Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting CI
Apr. 04 Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 177.5 45.77 17.3 25.57 - -
Enterprise Value (EV) 1 32.19 -53.31 17.3 25.57 25.57 25.57
P/E ratio -4.36 x -0.94 x -0.57 x -1.05 x -1.17 x -1.05 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -4.82 x -0.92 x -0.47 x -0.71 x -0.61 x -0.52 x
EV / FCF -5,496,715 x -1,163,320 x - - - -
FCF Yield -0% -0% - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 30,597 30,720 24,997 25,071 - -
Reference price 2 5.800 1.490 0.6920 1.020 1.020 1.020
Announcement Date 3/10/22 3/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - -
EBITDA 1 - -19.24 -36.8 -49.57 -36.49 -35.81 -41.82 -49.51
EBIT 1 - -19.45 -37.48 -50.19 -37.06 -34.92 -40.4 -46.93
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 - -20.1 -36.79 -48.59 -34.1 -32.12 -37.05 -41.17
Net income 1 -16.74 -20.2 -36.79 -48.59 -34.1 -30.31 -39.23 -44.6
Net margin - - - - - - - -
EPS 2 -1.160 -12.53 -1.330 -1.580 -1.220 -0.9700 -0.8700 -0.9700
Free Cash Flow - -18.91 -32.28 -39.35 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 1/15/21 3/25/21 3/10/22 3/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA 1 - - - - - - - - - -8.007 -8.329 -8.677 -9.091 -9.71
EBIT 1 -10.32 -9.413 -12.49 -10.71 -13.94 -13.05 -11.01 -10.18 -7.737 -8.142 -8.1 -8.605 -8.799 -9.421
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -9.685 -9.366 -12.4 - -13.42 -12.23 - - - -7.414 -7.66 -7.891 -8.128 -8.441
Net income 1 -9.685 -9.366 -12.4 -10.54 -13.42 -12.23 -10.18 -9.386 -7.124 -7.414 -6.845 -7.414 -7.677 -8.372
Net margin - - - - - - - - - - - - - -
EPS 2 -0.3200 -0.2700 -0.4000 -0.3400 -0.4400 -0.4000 -0.3300 -0.3100 -0.2800 -0.3000 -0.2900 -0.2300 -0.2350 -0.2500
Dividend per Share 2 - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/10/22 5/10/22 8/9/22 11/8/22 3/28/23 5/9/23 8/3/23 11/7/23 2/28/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 16 145 99.1 - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - -18.9 -32.3 -39.3 - - - -
ROE (net income / shareholders' equity) - - - -38.9% - -41.5% -54.3% -62.6%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 1.21 2.03 0.32 - - - -
Capex / Sales - - - - - - - -
Announcement Date 1/15/21 3/25/21 3/10/22 3/28/23 2/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.02 USD
Average target price
4.667 USD
Spread / Average Target
+357.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SENSEI BIOTHERAPEUTICS, INC. Stock Sensei Biotherapeutics, Inc.
+47.40% 25.57M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SNSE Stock
  4. Financials Sensei Biotherapeutics, Inc.